



Review

Discovery and development of safe-in-man broad-spectrum antiviral agents



Petter I. Andersen^{a,1}, Aleksandr Ianevski^{a,1}, Hilde Lysvand^a, Astra Vitkauskienė^b, Valentyn Oksenysh^a, Magnar Bjørås^a, Kaidi Telling^c, Irja Lutsar^d, Uga Dumpis^e, Yasuhiko Irie^c, Tanel Tenson^c, Anu Kantele^f, Denis E. Kainov^{a,c,g,*}

^a Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway

^b Department of Laboratory Medicine, Lithuanian University of Health Science, 44307 Kaunas, Lithuania

^c Institute of Technology, University of Tartu, 50090 Tartu, Estonia

^d Institute of Medical Microbiology, University of Tartu, Tartu 50411, Estonia

^e Latvian Biomedical Research and Study Centre, Riga 1067, Latvia

^f Helsinki University Hospital (HUS) and University of Helsinki, Helsinki 00290, Finland

^g Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014 Helsinki, Finland

ARTICLE INFO

Article history:

Received 24 January 2020

Received in revised form 7 February 2020

Accepted 11 February 2020

Keywords:

Virus

Antiviral drug

Drug discovery and development

Broad-spectrum antiviral agents

BSAAs

ABSTRACT

Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs, i.e. compounds targeting viruses belonging to two or more viral families) could provide additional protection of the general population from emerging and re-emerging viral diseases, reinforcing the arsenal of available antiviral options. Here, we review discovery and development of BSAAs and summarize the information on 120 safe-in-man agents in a freely accessible database (<https://drugvirus.info/>). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand the spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging viral infections as well as co-infections.

© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Viruses are one of the major causes of morbidity and mortality in the world (DALYs and Collaborators, 2018; Disease et al., 2018; Howard and Fletcher, 2012; WHO, 2015). Antiviral drugs and vaccines are used to fight viral infections in human (De Clercq and Li, 2016; Marston et al., 2014). Previously, there has been a focus on “one drug, one virus” dogma, which relied on targeting virus-specific factors. A counterpoint to this is the “one drug, multiple viruses” paradigm, which came with the discovery of broad-spectrum antiviral agents (BSAAs), small-molecules that inhibit a wide range of human viruses (Bekerman and Einav, 2015; de Clercq and Montgomery, 1983; Debing et al., 2015; Ianevski et al., 2019; Rada and Dragun, 1977; Sidwell et al., 1972). This paradigm was based on the observation that different viruses utilize similar pathways and host factors to replicate inside a cell (Bosl et al.,

2019). Although the concept of BSAAs has been around for almost 50 years, the field received a new impetus with recent outbreaks of Ebola, Zika, Dengue, influenza and other viral infections, the discovery of novel host-directed agents, as well as development of drug repositioning methodology.

Drug repurposing, also called repositioning, redirecting, reprofiling, is a strategy for generating additional value from an existing drug by targeting disease other than that for which it was originally intended (Nishimura and Hara, 2018; Pushpakom et al., 2019). This has significant advantages over new drug discovery since chemical synthesis steps, manufacturing processes, reliable safety, and pharmacokinetic properties in pre-clinical (animal model) and early clinical developmental phases (phase 0, I and IIa) are already available (Figure 1). Therefore, repositioning of launched or even failed drugs to viral diseases provides unique translational opportunities, including a substantially higher probability of success to market as compared with developing new virus-specific drugs and vaccines, and a significantly reduced cost and timeline to clinical availability (Ianevski et al., 2019; Pizzorno et al., 2019; Zheng et al., 2018).

Here, we detail the steps of BSAA repurposing, from discovery of novel antiviral activities in cell culture to post-market studies.

* Corresponding author at: Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
E-mail address: denis.kainov@ntnu.no (D.E. Kainov).

¹ Contributed equally.




Figure 1. Discovery of novel activities and follow-up development of broad-spectrum antiviral agents (BSAAs). Yellow shading indicates a process of discovery and development of safe-in-man BSAAs, for which pharmacokinetic (PK) properties in pre-clinical (animal model) and early clinical developmental phases (phase 0–IIa trials) are already available. Abbreviations: ESCs, human embryonic stem cells; iPSCs, human induced pluripotent stem cells (iPSCs).

Moreover, we summarized currently available information on BSAAs in freely available database, focusing on those antivirals, which have been already tested in human as antivirals, anti-bacterials, antiprotozoals, anthelmintics, etc. Finally, we discuss future perspectives of using safe-in-man BSAAs for treatment of emerging and re-emerging viral infections as well as viral and bacterial co-infections.

Discovery and development of safe-in-man BSAAs

Discovery of novel BSAA activities in immortalized cell cultures and co-cultures

The discovery of novel activities of BSAAs starts with exposing cells to the candidate antiviral agent at different concentrations and infecting the cells with a virus or mock. Immortalized cancerous cell cultures and co-cultures, which express appropriate viral receptors, are most commonly used in this first step. The half-maximal cytotoxic concentrations (CC_{50}) for a compound are calculated based on their dose-response curves obtained on mock-infected cells. The half-maximal effective concentrations (EC_{50}) are calculated based on the analysis of curves obtained on infected cells. Statistical analyses can help to determine if the differences between CC_{50} and EC_{50} are significant, given the inherent variability of the experiment (Meneghini and Hamasaki, 1967). A relative effectiveness of a drug is defined as selectivity index ($SI = CC_{50}/EC_{50}$).

Cell viability assays and cell death assays are commonly used to assess the cytotoxicity and efficacy of BSAAs (Figure 2A). Cell viability assays include MTT, MTS, resazurin or similar assays, mitochondrial membrane potential-dependent dyes-based assays, esterase cleaved dye-based assays, ATP-ADP assays, and assays that measure glycolytic flux and oxygen consumption. Other cell death assays include LDH enzyme leakage assays, membrane impermeable dye-based assays, and apoptosis assays, such as Annexin V, TUNEL, and caspase assays (Shen et al., 2019). For example, the Cell Titer Glo (CTG) assay quantifies ATP, an indicator of metabolically active living cells, whereas Cell Tox Green assay uses fluorescent asymmetric cyanine dye that stains the DNA of dead cells (Bosl et al., 2019; Bulanova et al., 2017; Ianevski et al., 2018; Muller et al., 2014).

Viral strains or cell lines expressing reporter proteins are also used to assess the efficacy of BSAAs in infected cells. For example, TZM-bl cells expressing firefly luciferase under control of HIV-1 LTR promoter allowed quantitation of BSAA action on HIV-1 infection (tat-protein expression by integrated HIV-1 provirus) using firefly luciferase assay (Sarzotti-Kelsoe et al., 2014; Xing et al., 2016). RFP-expressing RVFV, nanoLuc-expressing CHIKV and RRV, as well as GFP-expressing FLUAV, HCV and HMPV also allowed identification of novel activities of several BSAAs (Andersen et al., 2019b; Bosl et al., 2019; de Graaf et al., 2007; Habjan et al., 2008; Ianevski et al., 2018; Jupille et al., 2011; Kittel et al., 2004; Lee et al., 2017; Utt et al., 2016). In addition, qPCR/RT-qPCR, RNA/DNA sequencing, RNA/DNA hybridization, immuno- and plaque assays as well as CRISPR-Cas9 systems could be used for detection of

inhibitory effects of BSAAs (Boonham et al., 2014; Fischer et al., 2017; König et al., 2019; Laamiri et al., 2018; Landry, 1990; Perez et al., 2013; Sashital, 2018; Zhou et al., 2018). Interestingly, CRISPR-Cas9, siRNA and shRNA approaches were used for identification of BSAA targets (Deans et al., 2016; Puschnik et al., 2017).

Novel anti-HSV-2 and anti-EV1 activities of emetine were discovered recently using CTG/plaque assays in human non-malignant RPE cells. Moreover, novel antiviral activities of the drug were identified using RFP-expressing RVFV, and GFP-expressing HMPV or FLUAV strains in RPE cells (Andersen et al., 2019a). Given that emetine also inhibits ZIKV, EBOV, RABV, CMV, HCoV-OC43 and HIV-1 infections (Chaves Valadao et al., 2015; MacGibeny et al., 2018; Mukhopadhyay et al., 2016; Shen et al., 2019; Yang et al., 2018), and that it is an FDA-approved anti-protozoal drug, it may represent a promising safe-in-man BSAA candidate.

Evaluation of BSAAs in human primary cell culture and co-cultures

Immortalized cell cultures/co-cultures and reporter viral strains represent excellent model systems for the discovery of novel activities of safe-in-man BSAAs. However, these genetically modified systems have certain limitations (attenuated or incomplete virus replication cycle, accumulation of mutations during repeated cell and virus passaging, defective innate immune responses and viral counter-responses, etc.) (Carter and Shieh, 2015). Thereby, novel antiviral activities of BSAAs should be further validated in primary human cells using different viral strains (including wild-type viruses), different viral loads, different times of compound addition, different endpoint measurements and compound concentration range. Primary cell cultures give more accurate images of drug responses (Alves et al., 2018; Denisova et al., 2012; Koban et al., 2018; Postnikova et al., 2018). They have a low population doubling level and therefore more closely recapitulate the physiological conditions observed in vivo.

Primary cells are cells isolated directly from tissues or blood using enzymatic or mechanical methods. The cells are characterized by their high degrees of specialization, are often fully differentiated and thus require defined culture conditions (serum-free media) in order to preserve their original phenotype. Peripheral blood mononuclear (PBMC), placental, amniotic and fetal primary cultures as well as vaginal/cervical epithelial and male germ cells have been used intensively to validate BSAA activity (Barrows et al., 2016; Denisova et al., 2012; Fink et al., 2018; Rausch et al., 2017; Robinson et al., 2018). Although primary cell cultures are relevant systems for validation of BSAAs, there are technical difficulties limiting their use, such as ethical issues, purity of population of primary cells, and limited shelf life of the cells. In addition, age, race, sex and other genetic and epigenetic factors of donor cells should be considered to determine common biological effect across a significant number of donors thereby avoiding minor variants (Lee et al., 2014; Zhang et al., 2013).

The obstacles associated with use of human primary cell cultures can be bypassed using human embryonic stem cells (ESCs) and human induced pluripotent stem cells (iPSCs). ESCs are isolated from surplus human embryos, whereas iPSCs are obtained




Figure 2. ABC of BSAA development process. (A) Testing BSAA toxicity (left panel) and efficacy (right panel) in immortalized cell cultures and co-cultures. (B) Testing BSAA toxicity (left panel) and efficacy (right panel) in animal models. If BSAA is repositioned from another disease (i.e. its PK/PD and toxicity profiles are available for the animal model) it could bypass the safety studies. (C) Clinical trials of BSAA. (Left panel) Pharmacokinetics (PK) and safety studies. (Right panel) Efficacy studies. If the drug is repositioned from another disease (i.e. its safety profile in man is available) it could bypass the PK and safety studies in man.

by reprogramming somatic cells. These cells proliferate extensively and retain multi-lineage activity, which allows them to generate virtually any cell type of the body. The ESCs- and iPSC-derived cells have been used successfully to investigate the efficacy of several BSAA against HBV, ZIKV, CHIKV and HSV-1 infections (Table S1) (Ferreira et al., 2019; Iwasawa et al., 2019; Lanko et al., 2017; Simonin et al., 2019; Xia et al., 2017; Zhou et al., 2017).

iPSCs, ESCs and primary tissue cells can be used to generate complex cultures termed organoids. Organoids are miniature and simplified version of organs. Establishing human airway, gut, skin, cerebral, liver, kidney, breast, retina and brain organoids allowed researchers to study toxicity and efficacy of several safe-in-man BSAA against coronaviruses, influenza, enteroviruses, rotaviruses and flaviviruses (Li et al., 2017; Sacramento et al., 2017; Watanabe et al., 2017; Xu et al., 2016; Yin et al., 2015; Yin et al., 2018; Yin et al., 2016; Zhou et al., 2017). However, iPSCs, ESCs and iPSCs/ESCs-derived organoids have the same disadvantages as human primary cells (genetic differences, line-to-line and organoid batch-to-batch

variability). On the other hand, these models allow researchers to predict the behavior of viruses in vivo and, therefore, to reduce animal use and in cases where animal models are unavailable to initiate clinical trials.

For example, novel anti-ZIKV activities of enoxacin, amodiaquine and niclosamide were discovered recently using human neural progenitor cells, human pluripotent stem cell-derived cortical neural progenitor cells, and human induced neural stem cells, respectively (Cairns et al., 2018; Xu et al., 2019; Zhou et al., 2017). Enoxacin is an oral broad-spectrum fluoroquinolone antibiotic, which also possesses anti-HCV and anti-HIV-1 activities in immortalized cell cultures (Kashiwase et al., 1999; Young et al., 2010). Amodiaquine is an anti-malaria drug, which also possesses antiviral activities against DENV, HCV, RRV, SIN, WNV, EBFV, LASV, RABV, VZV, and HSV-1 in immortalized cell cultures (Boonyasuppayakorn et al., 2014; Hulseberg et al., 2019; Mazzon et al., 2019). Niclosamide is an orally bioavailable anthelmintic drug which inhibits the broadest range of viruses in vitro and, in

some cases, in vivo (Cairns et al., 2018; Fang et al., 2013; Huang et al., 2017; Hulseberg et al., 2019; Jurgeit et al., 2012; Kao et al., 2018; Mazzon et al., 2019; Stachulski et al., 2011; Wang et al., 2016; Wu et al., 2004). These safe-in-man BSAs represent promising drug candidates.

Evaluation of BSAs in animal models

In vitro and ex vivo models do not fully reflect the complexity and physiology of living organisms. Therefore, several in vivo models have been developed to test novel antiviral activities of BSAs. These include immunocompetent and genetically or chemically immunocompromised mice, guinea pigs, hamsters, ferrets, pigs, macaques and other animals (Figure 2B) (Alves et al., 2018; Haese et al., 2016; Louz et al., 2013; Morrison and Diamond, 2017; Taylor, 2017; Thangavel and Bouvier, 2014). PK/PD studies determine drug absorption, dosage and half-life of BSAs. Toxicological studies determine if the drugs have any adverse effects on the tissues and organs of the animals and define the dosage of adverse effects (Alabaster and In Vivo Pharmacology Training Group, 2002; Parasuraman, 2011; Rizk et al., 2017). Studying the efficacy of BSAs is generally done by treating the animal with the drug or vehicle and infecting it with a virus of interest. Endpoints are usually body weight/ mortality (depending on the virus), histopathology, virus titers in organs, presence of clinical signs and development of immunity (Oh and Hurt, 2016; Smeed and Barnard, 2013). Although animal models can give the initial characterization of BSA, it is important to keep in mind that they differ significantly from humans, with respect to symptoms, disease manifestation, susceptibility, immune responses, pathogenesis, and pharmacokinetics (Barré-Sinoussi and Montagnutelli, 2015; Shanks et al., 2009).

Often animals require higher concentration of an experimental antiviral as compared to effective in vitro concentrations. Moreover, it is relatively difficult to achieve micromolar EC₅₀ in vivo. For example, aminoglycoside antibiotics, kasugamycin and neomycin were successfully tested against ZIKV, FLUAV, and HSV-2 infections in mice (Gopinath et al., 2018). Polyether antibiotic salinomycin also showed anti-FLUAV effect in mice (Jang et al., 2018). In addition, investigational anticancer agent, flavopiridol, was effective against FLUAV in mice (Soderholm et al., 2016). These findings support further development of these and other BSAs.

Clinical trials and post-clinical studies of BSAs

Clinical trials are the most critical and time-consuming step of a drug candidates' journey to being approved (Figure 2C). However, safe-in-man BSAs make this journey relatively short, because they have been already at phase 0, I and, sometime, at IIa of clinical trials as antibacterial, antiparasitic, anticancer, etc. agent; i.e. they have been administered at sub-therapeutic doses to healthy volunteers to ensure the drugs are not harmful to the participants. Thus, safe-in-man BSAs enter phase II and III, which assess the efficacy, effectiveness, safety and side effects of the drugs in clinic. It is important, however, to differentiate acute and chronic viral infections when repurposing BSAs, given that drug concentrations and duration of the treatment could be different, and therefore, drug safety issues should be considered.

For phase II, patients with the viral disease in question are invited to join the study, where they are administered the BSAs at the ideal therapeutic doses. Phase III is the longest of the phases, and includes multiple levels of securities to the studies, such as the use of placebos and double-blinded studies, to ensure the data is as unbiased as possible. Upon completing phase III, depending on its performance and efficacy, BSAs may end either being approved or dropped. The U.S Food and Drug Administration (FDA) estimates

that only 25–30% BSA candidates that enter phase III are approved for use in the public (U.S Food and Drug Administration, 2018). After approval and marketing of the drug, phase IV may be initiated to follow up on the use of the drug in public, to surveil for rare effects (U.S Food and Drug Administration, 2018; Umscheid et al., 2011).

Forty-eight safe-in-man BSAs undergo clinical studies as antivirals. There are currently 21 compounds in phase I, 34 agents in phase II and 11 compounds in phase III clinical trials. For example, nitazoxanide, remdesivir and brincidofovir are under clinical investigations against different viral infections (NCT03336619, NCT00302640, NCT03605862, NCT03719586, NCT01276756, NCT03905655, NCT01529073, NCT03395405, NCT03216967, NCT01431326, NCT02087306, NCT01769170).


Twenty-one BSAs were approved by FDA, EMA or other agencies. These BSAs altogether target 15 viruses. For example, favipiravir, also known as T-705, was approved against FLUAV in Japan; cidofovir is an injectable antiviral medication used as a treatment for CMV retinitis in people with AIDS; ribavirin, also known as tribavirin, is used for treatment of RSV and HCV infections; pleconaril is used against viruses in the picornaviridae family, including enterovirus and rhinovirus; and valacyclovir is used against CMV, EBV, HBV, HSV-1, HSV-2 and VZV infections.

Twenty BSAs are undergoing surveillance studies (phase IV). Azithromycin, chloroquine, cyclosporine, ezetimibe, mycophenolic acid, nitazoxanide and rapamycin progressed to phase IV studies without approvals from national or international authorities (NCT01779570, NCT02058173, NCT02564471, NCT00821587, NCT03360682, NCT02328963, NCT02768545, NCT01624948, NCT01770483, NCT02683291, NCT01624948, NCT01469884, NCT03901001, NCT01412515, NCT02990312).

BSA database

We have developed a database for safe-in-man BSAs, which is available at <https://drugvirus.info/> (Figure 3). The drug annotations were obtained from PubChem, DrugBank, DrugCentral, PubMed and clinicaltrials.gov databases (Table S1) (Kim et al., 2019; Ursu et al., 2019; Wishart et al., 2018). The information on virus families was exported from Virus Pathogen Database and Analysis Resource (Table S2) (Pickett et al., 2012). The database summarizes activities and developmental status of BSAs. We decided to set no limits for EC₅₀, SI and statistical significance because the studies were not harmonized (different cell lines, assays, end-point measurements, time of compound addition, etc.). The database allows interactive exploration of virus-BSA interactions. It also includes information on BSA targets. A feedback form is available on the website. The database will be updated upon request or as soon as a new safe-in-man BSA emerges or novel activity for an existing BSA is reported.

Altogether, the database contains 120 approved, investigational and experimental safe-in-man BSAs, which inhibit 86 human viruses, belonging to 25 viral families. The BSAs inhibit viral or host factors and block viral replication, reduce the viral burden to a level at which host immune responses can deal with it or facilitate apoptosis of infected cells (Table S1). Analysis of BSA targets and structures (Figure 4) revealed that the most abundant are nucleotide and nucleoside analogues which inhibit viral RNA and DNA polymerases. Imatinib, erlotinib, gefitinib, and dasatinib, which inhibit tyrosine kinases, are the most abundant host-directed BSAs. Most of the host targets (except Bcl-xL protein) are essential for viral replication but redundant for the cell, which is critical for reducing putative toxicities associated with blocking cellular pathways. The limited diversity of the targets and scaffolds could slow down the development of BSA concept.





BSAAs as drug candidates for treatment of SARS-CoV-2 infections

No vaccines and drugs are available for prevention, prophylaxis and treatment of coronavirus infections in humans ([Eurosurveillance Editorial, 2020](#)). However, safe-in-man BSAs could be effective against SARS-CoV-2 and other coronaviruses ([Figure 5](#)). For example, teicoplanin, oritavancin, dalbavancin, monensin and emetine could be repurposed for treatment of COVID-19. Teicoplanin, ritavancin, dalbavancin and monensin are approved antibiotics, whereas emetine is an anti-protozoal drug. These drugs have been shown to inhibit several corona- as well as some other viral infections. Moreover, chloroquine and remdesivir were shown to effectively inhibit SARS-CoV-2 infection in vitro. In addition, clinical investigations into the effectiveness of lopinavir, ritonavir, remdesivir, hydroxychloroquine and arbidol against COVID-19 have started recently (NCT04252664; NCT0425487; NCT04255017; NCT04261517, NCT04260594).

BSAAs could be combined with other antiviral agents to obtain synergistic or additive effects against certain viruses (Cheng et al., 2019; Zheng et al., 2018). Several combination therapies which




Figure 5. Safe-in-man broad-spectrum antiviral agents and coronaviruses they inhibit. A snapshot is taken from <https://drugvirus.info/> website. Different shadings indicate different development status of BSAA. Grey shading indicates that the antiviral activity has not been either studied or reported.

include BSAA (such as abacavir/dolutegravir/lamivudine (Triumeq), darunavir/cobicistat/emtricitabine/tenofovir (Symtuza), lopinavir/ritonavir (Kaletra), ledipasvir/sofosbuvir and sofosbuvir/velpatasvir) became a standard for the treatment of HIV or HCV infections. Several synergistic drug combinations, such as obataclax/saliphenylhalamide and gemcitabine/pimodivir, could enter clinical studies and become effective treatment of ZIKV and FLUAV infections (Fu et al., 2016; Kuivanen et al., 2017).

By contrast to individual drugs, combinations of 2–3 BSAA could be used to target an even broader range of viruses (Fouquier and Guedj, 2015; Zheng et al., 2018). Such combinations could serve as front line therapeutics against poorly characterized emerging viruses or re-emerging drug-resistant viral strains. For example, a cocktail of nitazoxanide, favipiravir, and niclosamide could be developed for the treatment of viruses belonging to 11 families.

Other activities of BSAA

Fifty BSAA possess not only antiviral but also antibacterial activity (Figure 4; Table S1) (Schor and Einav, 2018). Moreover, 13 of the 50 agents are approved as antibiotics (2 withdrawn). These

agents with dual activity could be used for treatment of viral and bacterial co-infections or for the protection of patients from the secondary infections. For example, azithromycin could be used against FLUAV and *Chlamydomonas pneumoniae*, *Haemophilus influenzae*, *Mycoplasma pneumoniae* or *Streptococcus pneumoniae* infections (NCT01779570) (Mandell et al., 2007).

In addition, BSAA showed activity against a wide range of other medically important human pathogens, including fungi, protozoa and parasites (Table S1) (Montoya and Krysan, 2018), pointing out that some pathogens utilize common mechanisms to infect hosts. Moreover, structure-activity relationship analysis of BSAA suggests that some agents, such as doxycycline, artesunate, omeprazole, nitazoxanide, suramin, azithromycin, minocycline and chloroquine, could have novel antibacterial, antiparasitic, antifungal or anthelmintic activities (Figure 4). If confirmed, this could lead to development of broad-spectrum anti-infective drugs.

BSAA could also serve as treatment of other co-morbidities, therefore, simplifying the therapy and lowering its cost (Table S1). For example, the concomitant actions of ezetimibe and statins could be beneficial for treatment of both hypertension and several viral infections in patients with these co-morbidities (NCT00908011, NCT00099684, NCT00843661, NCT03490097, NCT00994773, NCT00441493).

Conclusions and future perspectives

Here we reviewed a process of BSAA development and summarized information on 120 safe-in-man agents in freely available database. We hope that further pre-clinical and clinical studies on BSAA will be harmonized, and data collection will be standardized. Furthermore, the follow-up studies as well as the results of on-going, finalized or terminated clinical trials will be made publicly available to allow prioritization and translation of emerging and existing BSAA into clinical practice. This would allow BSAA to play a pivotal role in the battle against emerging and re-emerging viral diseases.

Discovery of novel as well as repositioning existing safe-in-man BSAA may shorten time and resources needed for development of virus-specific drugs and vaccines. In the future, BSAA will have a global impact by decreasing morbidity and mortality from viral and other diseases, maximizing the number of healthy life years, improving the quality of life of infected patients and decreasing the costs of patient care.

Conflicts of interest

The authors declare no conflict of interest.

Funding sources

This study was supported by the European Regional Development Fund, the Mobilias Pluss Project MOBTT39 (to D.K.).

Ethical approval

Approval was not required.

Acknowledgments

We thank Katarzyna Kolasa for illustrations. This manuscript has been released as a pre-print (doi: <https://10.20944/preprints201910.0144.v46>). We thank the European Regional Development Fund, the Mobilias Pluss Project MOBTT39.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.ijid.2020.02.018>.

References

- Alabaster V, In Vivo Pharmacology Training Group. The fall and rise of in vivo pharmacology. *Trends Pharmacol Sci* 2002;23:13–8.
- Alves MP, Vielle NJ, Thiel V, Pfaender S. Research models and tools for the identification of antivirals and therapeutics against Zika virus infection. *Viruses* 2018;10:.
- Andersen PI, Krpina K, Ianevski A, Shtaida N, Jo E, Yang J, et al. Novel antiviral activities of obataclax, emetine, niclosamide, brequinar, and homoharringtonine. *Viruses* 2019a;11:.
- Andersen PI, Krpina K, Ianevski A, Shtaida N, Jo E, Yang J, et al. Novel antiviral activities of obataclax, emetine, niclosamide, brequinar, and homoharringtonine. *Viruses* 2019b;11: pii: E964.
- Barré-Sinoussi F, Montagnutelli X. Animal models are essential to biological research: issues and perspectives. *Future Sci OA* 2015;1: FSO63-FSO63.
- Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. *Cell Host Microbe* 2016;20:259–70.
- Bekerman E, Einav S. Infectious disease. Combating emerging viral threats. *Science* 2015;348:282–3.
- Boonham N, Kreuze J, Winter S, van der Vlugt R, Bergervoet J, Tomlinson J, et al. Methods in virus diagnostics: from ELISA to next generation sequencing. *Virus Res* 2014;186:20–31.
- Boonyasuppayakorn S, Reichert ED, Manzano M, Nagarajan K, Padmanabhan R. Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. *Antiviral Res* 2014;106:125–34.
- Bosi K, Ianevski A, Than TT, Andersen PI, Kuivanen S, Teppor M, et al. Common nodes of virus–host interaction revealed through an integrated network analysis. *Front. Immunol* 2019;4:2186.
- Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, et al. Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins. *Viruses* 2017;9:.
- Cairns DM, Boorgu D, Levin M, Kaplan DL. Niclosamide rescues microcephaly in a humanized in vivo model of Zika infection using human induced neural stem cells. *Biol Open* 2018;7:.
- Carter M, Shieh J. Chapter 14 – cell culture techniques. In: Carter M, Shieh J, editors. *Guide to research techniques in neuroscience*. Second edition San Diego: Academic Press; 2015. p. 295–310.
- Chaves Valadao AL, Abreu CM, Dias JZ, Arantes P, Verli H, Tanuri A, et al. Natural plant alkaloid (emetine) inhibits HIV-1 replication by interfering with reverse transcriptase activity. *Molecules* 2015;20:11474–89.
- Cheng YS, Williamson PR, Zheng W. Improving therapy of severe infections through drug repurposing of synergistic combinations. *Curr Opin Pharmacol* 2019;48:92–8.
- DALYs, G.B.D., Collaborators, H. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1859–922.
- De Clercq E, Li G. Approved antiviral drugs over the past 50 years. *Clin Microbiol Rev* 2016;29:695–747.
- de Clercq E, Montgomery JA. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. *Antiviral Res* 1983;3:17–24.
- de Graaf M, Herfst S, Schrauwen EJ, van den Hoogen BG, Osterhaus AD, Fouchier RA. An improved plaque reduction virus neutralization assay for human metapneumovirus. *J Virol Methods* 2007;143:169–74.
- Deans RM, Morgens DW, Okesli A, Pillay S, Horlbeck MA, Kampmann M, et al. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. *Nat Chem Biol* 2016;12:361–6.
- Debing Y, Neyts J, Delang L. The future of antivirals: broad-spectrum inhibitors. *Curr Opin Infect Dis* 2015;28:596–602.
- Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, et al. Obataclax, saliphenylhalamide, and gemcitabine inhibit influenza A virus infection. *J Biol Chem* 2012;287:35324–32.
- Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1789–858.
- Eurosurveillance Editorial T. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. *Euro Surveill* 2020;.
- Fang J, Sun L, Peng G, Xu J, Zhou R, Cao S, et al. Identification of three antiviral inhibitors against Japanese encephalitis virus from library of pharmacologically active compounds 1280. *PLoS One* 2013;8:e78425.
- Ferreira AC, Reis PA, de Freitas CS, Sacramento CQ, Villas Boas Hoelz L, Bastos MM, et al. Beyond members of the flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. *Antimicrob Agents Chemother* 2019;63:.
- Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ, Wang R, et al. The antiviral drug arbidol inhibits Zika virus. *Sci Rep* 2018;8:8989.
- Fischer C, Torres MC, Patel P, Moreira-Soto A, Gould EA, Charrel RN, et al. Lineage-specific real-time RT-PCR for yellow fever virus outbreak surveillance, Brazil. *Emerg Infect Dis* 2017;23:1867–71.
- Fouquier J, Guedj M. Analysis of drug combinations: current methodological landscape. *Pharmacol Res Perspect* 2015;3:e00149.
- Fu Y, Gaeleings L, Soderholm S, Belanov S, Nandania J, Nyman TA, et al. JN872 inhibits influenza A virus replication without altering cellular antiviral responses. *Antiviral Res* 2016;133:23–31.
- Gopinath S, Kim MV, Rakib T, Wong PW, van Zandt M, Barry NA, et al. Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner. *Nat Microbiol* 2018;3:611–21.
- Habjan M, Penski N, Spiegel M, Weber F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. *J Gen Virol* 2008;89:2157–66.
- Haese NN, Broeckel RM, Hawman DW, Heise MT, Morrison TE, Streblow DN. Animal models of Chikungunya virus infection and disease. *J Infect Dis* 2016;214:S482–7.
- Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected? *Emerg Microbes Infect* 2012;1:e46.
- Huang L, Yang M, Yuan Y, Li X, Kuang E. Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation. *Antiviral Res* 2017;138:68–78.
- Hulseberg CE, Feneant L, Szymanska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, et al. Arbidol and other low-molecular-weight drugs that inhibit lassa and Ebola viruses. *J Virol* 2019;93:.
- Ianevski A, Andersen PI, Merits A, Bjorås M, Kainov D. Expanding the activity spectrum of antiviral agents. *Drug Discov Today* 2019;24:1224–8.
- Ianevski A, Zusinaite A, Kuivanen S, Strand M, Lysvand H, Teppor M, et al. Novel activities of safe-in-human broad-spectrum antiviral agents. *Antiviral Res* 2018;154:174–82.
- Iwasawa C, Tamura R, Sugiura Y, Suzuki S, Kuzumaki N, Narita M, et al. Increased cytotoxicity of herpes simplex virus thymidine kinase expression in human induced pluripotent stem cells. *Int J Mol Sci* 2019;20:.
- Jang Y, Shin JS, Yoon YS, Go YY, Lee HW, Kwon OS, et al. Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and viral matrix protein 2 function. *J Virol* 2018;92:.
- Jupille HJ, Oko L, Stoermer KA, Heise MT, Mahalingam S, Gunn BM, et al. Mutations in nsP1 and PE2 are critical determinants of Ross River virus-induced musculoskeletal inflammatory disease in a mouse model. *Virology* 2011;410:216–27.
- Jurgeit A, McDowell R, Moese S, Meldrum E, Schwendener R, Greber UF. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. *PLoS Pathog* 2012;8:e1002976.
- Kao JC, Huangfu WC, Tsai TT, Ho MR, Jhan MK, Shen TJ, et al. The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR. *PLoS Negl Trop Dis* 2018;12:e0006715.
- Kashiwase H, Momota K, Ohmine T, Komai T, Kimura T, Katsube T, et al. A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication. *Chemotherapy* 1999;45:48–55.
- Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update: improved access to chemical data. *Nucleic Acids Res* 2019;47:D1102–9.
- Kittel C, Sereinig S, Perko B, Stasakova J, Romanova J, Wolkerstorfer A, et al. Rescue of influenza virus expressing GFP from the NS1 reading frame. *Virology* 2004;324:67–73.
- Koban R, Neumann M, Daus A, Bloch O, Nitsche A, Langhammer S, et al. A novel three-dimensional cell culture method enhances antiviral drug screening in primary human cells. *Antiviral Res* 2018;150:20–9.
- König A, Yang J, Jo E, Park KHP, Kim H, Than TT, et al. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2–NTCP cells. *J Hepatol* 2019;71:289–300.
- Kuivanen S, Beshpalov MM, Nandania J, Ianevski A, Velagapudi V, De Brabander JK, et al. Obataclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism. *Antiviral Res* 2017;139:117–28.
- Laamiri N, Aouini R, Marnissi B, Ghram A, Hmila I. A multiplex real-time RT-PCR for simultaneous detection of four most common avian respiratory viruses. *Virology* 2018;515:29–37.
- Landry ML. Nucleic acid hybridization in viral diagnosis. *Clin Biochem* 1990;23:267–77.
- Lank K, Eggermont K, Patel A, Kaptein S, Delang L, Verfaillie CM, et al. Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals. *Antiviral Res* 2017;145:82–6.
- Lee M, Yang J, Jo E, Lee JY, Kim HY, Bartschschlager R, et al. A novel inhibitor IDPP interferes with entry and egress of HCV by targeting glycoprotein E1 in a genotype-specific manner. *Sci Rep* 2017;7:44676.
- Lee MN, Ye C, Villani AC, Raj T, Li W, Eisenhaure TM, et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. *Science* 2014;343:1246980.
- Li C, Deng YQ, Wang S, Ma F, Aliyari R, Huang XY, et al. 25-Hydroxycholesterol protects host against Zika virus infection and its associated microcephaly in a mouse model. *Immunity* 2017;46:446–56.
- Lou Z, Bergmans HE, Loos BP, Hoebe R. Animal models in virus research: their utility and limitations. *Crit Rev Microbiol* 2013;39:325–61.
- MacGibeny MA, Koyuncu OO, Wirblich C, Schnell MJ, Enquist LW. Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons. *PLoS Pathog* 2018;14:e1007188.
- Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;44(Suppl 2):S27–72.

- Marston HD, Folkers GK, Morens DM, Fauci AS. Emerging viral diseases: confronting threats with new technologies. *Sci Transl Med* 2014;6:253ps210.
- Mazzoni M, Ortega-Prieto AM, Imrie D, Luft C, Hess L, Czesio S, et al. Identification of broad-spectrum antiviral compounds by targeting viral entry. *Viruses* 2019;11:.
- Meneghini KA, Hamasaki DI. The electroretinogram of the iguana and Tokay gecko. *Vision Res* 1967;7:243–51.
- Montoya MC, Kryan DJ. Repurposing estrogen receptor antagonists for the treatment of infectious disease. *MBio* 2018;9:.
- Morrison TE, Diamond MS. Animal models of Zika virus infection, pathogenesis, and immunity. *J Virol* 2017;91.
- Mukhopadhyay R, Roy S, Venkatadri R, Su YP, Ye W, Barnaeva E, et al. Efficacy and mechanism of action of low dose emetine against human cytomegalovirus. *PLoS Pathog* 2016;12:e1005717.
- Muller KH, Kainov DE, El Bakkouri K, Saelens X, De Brabander JK, Kittel C, et al. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. *Br J Pharmacol* 2011;164:344–57.
- Muller KH, Spoden GA, Scheffer KD, Brunnhofer R, De Brabander JK, Maier ME, et al. Inhibition by cellular vacuolar ATPase impairs human papillomavirus uncoating and infection. *Antimicrob Agents Chemother* 2014;58:2905–11.
- Nishimura Y, Hara H. Editorial: drug repurposing: current advances and future perspectives. *Front Pharmacol* 2018;9:1068.
- Oh DY, Hurt AC. Using the ferret as an animal model for investigating influenza antiviral effectiveness. *Front Microbiol* 2016;7:.
- Parasuraman S. Toxicological screening. *J Pharmacol Pharmacother* 2011;2:74–9.
- Patil SA, Patil V, Patil R, Beamman K, Patil SA. Identification of novel 5,6-dimethoxyindan-1-one derivatives as antiviral agents. *Med Chem (Shariqah (United Arab Emirates))* 2017;13:787–95.
- Perez JT, Garcia-Sastre A, Manicassamy B. Insertion of a GFP reporter gene in influenza virus. *Curr Protocols in microbiology* 2013; Chapter 15, Unit 15G.14.
- Pickett BE, Greer DS, Zhang Y, Stewart L, Zhou L, Sun G, et al. Virus pathogen database and analysis resource (ViPR): a comprehensive bioinformatics database and analysis resource for the coronavirus research community. *Viruses* 2012;4:3209–26.
- Pizzorno, A., Padey, B., Terrier, O., Rosa-Calatrava, M., 2019. Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy. 10.
- Postnikova E, Cong Y, DeWald LE, Dyall J, Yu S, Hart BJ, et al. Testing therapeutics in cell-based assays: factors that influence the apparent potency of drugs. *PLoS One* 2018;13:e0194880.
- Puschnik AS, Majzoub K, Ooi YS, Carette JE. A CRISPR toolbox to study virus-host interactions. *Nat Rev Microbiol* 2017;15:351–64.
- Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. *Nat Rev Drug Discov* 2019;18:41–58.
- Rada B, Dragun M. Antiviral action and selectivity of 6-azauridine. *Ann N Y Acad Sci* 1977;284:410–7.
- Rausch K, Hackett BA, Weinbren NL, Reeder SM, Sadovsky Y, Hunter CA, et al. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus. *Cell Rep* 2017;18:804–15.
- Rizk ML, Zou L, Savic RM, Dooley KE. Importance of drug pharmacokinetics at the site of action. *Clin Transl Sci* 2017;10:133–42.
- Robinson CL, Chong ACN, Ashbrook AW, Jeng G, Jin J, Chen H, et al. Male germ cells support long-term propagation of Zika virus. *Nat Commun* 2018;9:2090.
- Sacramento CQ, de Melo GR, de Freitas CS, Rocha N, Hoelz LV, Miranda M, et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. *Sci Rep* 2017;7:40920.
- Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, et al. Optimization and validation of the T2M-bl assay for standardized assessments of neutralizing antibodies against HIV-1. *J Immunol Methods* 2014;409:131–46.
- Sashital DG. Pathogen detection in the CRISPR-Cas era. *Genome Med* 2018;10:32.
- Schor S, Einav S. Combating intracellular pathogens with repurposed host-targeted drugs. *ACS Infect Dis* 2018;4:88–92.
- Shanks N, Greek R, Greek J. Are animal models predictive for humans?. *Philos Ethics Humanit Med* 2009;4:2.
- Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* 2017;9:.
- Shen L, Niu J, Wang C, Huang B, Wang W, Zhu N, et al. High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. *J Virol* 2019;93:.
- Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. *Science* 1972;177:705–6.
- Simonin Y, Erkilic N, Damodar K, Cle M, Desmetts C, Bollere K, et al. Zika virus induces strong inflammatory responses and impairs homeostasis and function of the human retinal pigment epithelium. *EBioMedicine* 2019;39:315–31.
- Smee DF, Barnard DL. Methods for evaluation of antiviral efficacy against influenza virus infections in animal models. *Methods Mol Biol (Clifton, N.J.)* 2013;1030:407–25.
- Soderholm S, Kainov DE, Ohman T, Denisova OV, Schepens B, Kuleskiy E, et al. Phosphoproteomics to characterize host response during influenza A virus infection of human macrophages. *Mol Cell Proteomics* 2016;15:3203–19.
- Stachulski AV, Pidathala C, Row EC, Sharma R, Berry NG, Lawrenson AS, et al. Thiazolidines as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. *J Med Chem* 2011;54:8670–80.
- Taylor G. Animal models of respiratory syncytial virus infection. *Vaccine* 2017;35:469–80.
- Thangavel RR, Bouvier NM. Animal models for influenza virus pathogenesis, transmission, and immunology. *J Immunol Methods* 2014;410:60–79.
- U.S Food and Drug Administration. The Drug Development Process: Step 3. 2018.
- Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. *Postgrad Med* 2011;123:194–204.
- Ursu O, Holmes J, Bologa CG, Yang JJ, Mathias SL, Stathias V, et al. DrugCentral 2018: an update. *Nucleic Acids Res* 2019;47:D963–70.
- Utt A, Quirin T, Saul S, Hellstrom K, Ahola T, Merits A. Versatile trans-replication systems for chikungunya virus allow functional analysis and tagging of every replicase protein. *PLoS One* 2016;11:e0151616.
- Wang YM, Lu JW, Lin CC, Chin YF, Wu TY, Lin LI, et al. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission. *Antiviral Res* [326.TD\$DIFF]2016;135:81–90.
- Watanabe M, Buth JE, Vishlaghi N, de la Torre-Ubieta L, Taxisidis J, Khakh BS, et al. Self-organized cerebral organoids with human-specific features predict effective drugs to combat Zika virus infection. *Cell Rep* 2017;21:517–32.
- WHO. WHO publishes list of top emerging diseases likely to cause major epidemics. 2015. www.who.int/medicines/ebola-treatment/WHO-list-of-top-emerging-diseases/en/.
- Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res* 2018;46:D1074–82.
- Wu CJ, Jan JT, Chen CM, Hsieh HP, Hwang DR, Liu HW, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. *Antimicrob Agents Chemother* 2004;48:2693–6.
- Xia Y, Carpentier A, Cheng X, Block PD, Zhao Y, Zhang Z, et al. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. *J Hepatol* 2017;66:494–503.
- Xing L, Wang S, Hu Q, Li J, Zeng Y. Comparison of three quantification methods for the T2M-bl pseudovirus assay for screening of anti-HIV-1 agents. *J Virol Methods* 2016;233:56–61.
- Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. *Nat Med* 2016;22:1101–7.
- Xu YP, Qiu Y, Zhang B, Chen G, Chen Q, Wang M, et al. Zika virus infection induces RNAi-mediated antiviral immunity in human neural progenitors and brain organoids. *Cell Res* 2019;29:265–73.
- Yang S, Xu M, Lee EM, Gorshkov K, Shiryaev SA, He S, et al. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. *Cell Discov* 2018;4:31.
- Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. *Antiviral Res* 2015;123:120–31.
- Yin Y, Chen S, Hakim MS, Wang W, Xu L, Dang W, et al. 6-Thioguanine inhibits rotavirus replication through suppression of Rac1 GDP/GTP cycling. *Antiviral Res* 2018;156:92–101.
- Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, et al. Mycophenolic acid potentially inhibits rotavirus infection with a high barrier to resistance development. *Antiviral Res* 2016;133:41–9.
- Young DD, Connelly CM, Grohmann C, Deiters A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. *J Am Chem Soc* 2010;132:7976–81.
- Zhang YH, Zhao Y, Li N, Peng YC, Giannoulou E, Jin RH, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. *Nat Commun* 2013;4:1418.
- Zheng W, Sun W, Simeonov A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. *Br J Pharmacol* 2018;175:181–91.
- Zhou L, Peng R, Zhang R, Li J. The applications of CRISPR/Cas system in molecular detection. *J Cell Mol Med* 2018;22:5807–15.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;.
- Zhou T, Tan L, Cederquist GY, Fan Y, Hartley BJ, Mukherjee S, et al. High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus infection in fetal-like organoids and adult brain. *Cell Stem Cell* 2017;21: 274–283.e275.. T.Pan. J.Zhang. Q.Li. X.Zhang. C.Bai. Glycopeptide antibiotics potentially inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)] *Biol Chem*291:.
- Zhou et al., 2020P.Zhou. X.L.Yang. X.G.Wang. B.Hu. L.Zhang. W.Zhang. A pneumonia outbreak associated with a new coronavirus of probable bat originNature.
- Zhou et al., 2017T.Zhou. L.Tan. G.Y.Cederquist. Y.Fan. B.J.Hartley. S.Mukherjee. High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus infection in fetal-like organoids and adult brainCell Stem Cell21: 274–283.e275.